



PATENT
ATTORNEY DOCKET NO. 50125/044001

Certificate of Mailing: Date of Deposit: 1/18/07

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as **first class mail** with sufficient postage on the date indicated above and is addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Colleen Lombard
Printed name of person mailing correspondence

Colleen Lombard
Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Michael Hallek et al.

Confirmation No.: 5985

Serial No.: 10/031,313

Art Unit: 1648

Filed: Jun. 3, 2002

Examiner: Chen, Stacey
Brown

Customer No.: 21559

Title: STRUCTURAL PROTEIN OF ADENO-ASSOCIATED VIRUS WITH
MODIFIED ANTIGENICITY, ITS PRODUCTION AND ITS USE

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Applicants submit the references listed on the enclosed Form PTO-1449, copies of which are enclosed, with the exception of U.S. patents and U.S. patent application publications


Submission of this statement is not a representation that a search has been made, nor is the inclusion of information in this statement an admission that the information is material to patentability.

This statement is being filed after a first Office action on the merits, but before the mailing of a final Office action or a Notice of Allowance. A check for \$180.00 in payment of the late submission fee set forth in 37 C.F.R. § 1.17(p) is enclosed.

If there are any other charges or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

Date: 18 Janay 2007



Karen L. Elbing, Ph.D.
Reg. No. 35,238

Clark & Elbing LLP
101 Federal Street
Boston, MA 02110
Telephone: 617-428-0200
Facsimile: 617-428-7045

F:\50125\50125.044001 Supp IDS filed 01.18.07.doc

Sheet 1 of 3

SUBSTITUTE FORM PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))	Attorney Docket No.	50125/044001
	Serial No.	10/031,313
	Applicant	Hallek et al.
	Filing Date	June 3, 2002
	Group	1648
	IDS Filed	January 18, 2007

U.S. PATENT DOCUMENTS			
Examiner's Initials	Document Number	Publication Date	Patentee or Applicant
	2001/031463	10/18/01	Kleinschmidt et al.
	2002/0192823	12/19/02	Bartlett et al.
	5,276,136	01/04/94	Skubitz et al.
	6,491,907	12/10/02	Rabinowitz et al.

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION				
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Translation (Yes/No)

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
	Anderson, "Human Gene Therapy," <i>Nature</i> 392:25-30 (1998).
	Asokan et al., "AAV Does the Shuffle," <i>Nature Biotechnology</i> 24:158-160 (2006).
	Buning et al., "Receptor Targeting of Adeno-Associated Virus Vectors," <i>Gene Therapy</i> 10:1142-1151 (2003).
	Grifman et al., "Incorporation of Tumor-Targeting Peptides into Recombinant Adeno-Associated Virus Capsids," <i>Molecular Therapy</i> 3:964-975 (2001).
	Hoque et al., "Nuclear Transport of the Major Capsid Protein is Essential for Adeno-Associated Virus Capsid Formation," <i>Journal of Virology</i> 73:7912-7915 (1999).
	Huttner et al., "Genetic Modifications of the Adeno-Associated Virus Type 2 Capsid Reduce the Affinity and the Neutralizing Effects of Human Serum Antibodies," <i>Gene Therapy</i> 10:2139-2147 (2003).
	Kmieciak, "Gene Therapy," <i>American Scientist</i> 87:240-247 (1999).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	



SUBSTITUTE FORM PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))	Attorney Docket No.	50125/044001
	Serial No.	10/031,313
	Applicant	Hallek et al.
	Filing Date	June 3, 2002
	Group	1648
	IDS Filed	January 18, 2007

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
	Maass et al., "Recombinant Adeno-Associated Virus for the Generation of Autologous, Gene-Modified Tumor Vaccines: Evidence for a High Transduction Efficiency into Primary Epithelial Cancer Cells," <i>Human Gene Therapy</i> 9:1049-1059 (1998).
	Maheshri et al., "Directed Evolution of Adeno-Associated Virus Yields Enhanced Gene Delivery Vectors," <i>Nature Biotechnology</i> 24:198-204 (2006).
	Marshall, "Second Child in French Trial is Found to Have Leukemia," <i>Science</i> 299:320 (2003).
	Meng et al., "Tumor Suppressor Genes as Targets for Cancer Gene Therapy," <i>Gene Therapy of Cancer Chapter 1</i> , pp. 3-18 (1999).
	Mizukami et al., "Adeno-Associated Virus Type 2 Binds to a 150-Kilodalton Cell Membrane Glycoprotein," <i>Virology</i> 217:124-130 (1996).
	Moskalenko et al., "Epitope Mapping of Human Anti-Adeno-Associated Virus Type 2 Neutralizing Antibodies: Implications for Gene Therapy and Virus Structure," <i>Journal of Virology</i> 74:1761-1766 (2000).
	Nicklin et al., "Efficient and Selective AAV2-Mediated Gene Transfer Directed to Human Vascular Endothelial Cells," <i>Molecular Therapy</i> 4:174-181 (2001).
	Perabo et al., "In Vitro Selection of Viral Vectors with Modified Tropism: The Adeno-Associated Virus Display," <i>Molecular Therapy</i> 8:151-157 (2003).
	Qing et al., "Human Fibroblast Growth Factor Receptor 1 is a Co-Receptor for Infection by Adeno-Associated Virus 2," <i>Nature Medicine</i> 5:71-77 (1999).
	Ried et al., "Adeno-Associated Virus Capsids Displaying Immunoglobulin-Binding Domains Permit Antibody-Mediated Vector Retargeting to Specific Cell Surface Receptors," <i>Journal of Virology</i> 76:4559-4566 (2002).
	Russell, "Replicating Vectors for Gene Therapy of Cancer: Risks, Limitations and Prospects," <i>European Journal of Cancer</i> 30A:1165-1171 (1994).
	Shi et al., "Insertional Mutagenesis of the Adeno-Associated Virus Type 2 (AAV2) Capsid Gene and Generation of AAV2 Vectors Targeted to Alternative Cell-Surface Receptors," <i>Human Gene Therapy</i> 12:1697-1711 (2001).
	Shi et al., "RGD Inclusion of VP3 Provides Adeno-Associated Virus Type 2 (AAV2)-Based Vectors with a Heparan Sulfate-Independent Cell Entry Mechanism," <i>Molecular Therapy</i> 7:515-525 (2003).
	Smith et al., "The Challenges of genome Sequence Annotation or 'the Devil is in the Details'," <i>Nature Biotechnology</i> , 15:1222-1223 (1997).
	Spear et al., "Evidence for Two Nucleotide Sequence Orientations Within the Terminal Repetition of Adeno-Associated Virus DNA," <i>Journal of Virology</i> 24:627-634 (1977).
	Starovasnik et al., "Structural Mimicry of a Native Protein by a Minimized Binding Domain," <i>Proc. Natl. Acad. Sci.</i>

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	



SUBSTITUTE FORM PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))	Attorney Docket No.	50125/044001
	Serial No.	10/031,313
	Applicant	Hallek et al.
	Filing Date	June 3, 2002
	Group	1648
	IDS Filed	January 18, 2007

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
	USA 94:10080-10085 (1997).
	Summerford et al., "Membrane Associated Heparan Sulfate Proteoglycan is a Receptor for Adeno-Associated Virus Type 2 Virions," <i>Journal of Virology</i> 72:1438-1445 (1998).
	Summerford et al., "αVβ5 Integrin: A Co-receptor for Adeno-Associated Virus Type 2 Infection," <i>Nature Medicine</i> 5:78-82 (1999).
	Tseng et al., "Evolutionary Model for Predicting Protein Function by Matching Local Surfaces: a Bayesian Monte Carlo Approach," The Ninth Annual Conference on Research in Computational Molecular Biology, May 14-18, 2005
	Verma et al., "Gene Therapy-Promises, Problems and Prospects," <i>Nature</i> 389:239-242 (1997).
	Wendtner et al., "Efficient Gene Transfer of CD40 Ligand into Primary B-CLL cells using recombinant Adeno-Associated Virus (rAAV) Vectors," <i>Blood</i> 100:1655-1661 (2002).
	White et al., "'Designer' Gene Therapy May Target Specific Body Area," <i>Business News</i> 2:1-2 (2003).
	White et al., "Targeted Gene Delivery to Vascular Tissue in Vivo by Tropism-Modified Adeno-Associated Virus Vectors," <i>Circulation</i> 109:513-519 (2004).
	Wobus et al., "Monoclonal Antibodies Against the Adeno-Associated Virus Type 2 (AAV-2) Capsid: Epitope Mapping and Identification of Capsid Domains Involved in AAV-2-Cell Interaction and Neutralization of AAV-2 Infection," <i>Journal of Virology</i> 74:9281-9293 (2000).
	Wu et al., "Mutational Analysis of the Adeno-Associated Virus Type 2 (AAV2) Capsid Gene and Construction of AAV2 Vectors with Altered Tropism," <i>Journal of Virology</i> 74:8635-8647 (2000).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	